1例局部晚期NSCLC的新辅助化疗联合免疫治疗及文献复习  

Neoadjuvant chemotherapy combined with immunotherapy for a case of locally advanced NSCLC and literature review

作　　者：杨光平 陈建成[1] 杨平华[1] 梁忠诚[1] YANG Guangping;CHEN Jiancheng;YANG Pinghua;LIANG Zhongcheng(Cardiothoracic Surgery Department,Jiangmen Xinhui District People's Hospital,Jiangmen 529100,China)

机构地区：[1]江门市新会区人民医院心胸外科,广东江门529100

出　　处：《临床医学研究与实践》2022年第16期22-24,共3页Clinical Research and Practice

基　　金：2021年度江门市卫生健康局科研立项项目(No.21A040)。

摘　　要：肺癌已经成为世界范围内发病率和致死率最高的恶性肿瘤。在肺癌的病理类型中,非小细胞肺癌(NSCLC)约占总数的80%。虽然医疗水平在不断提高,但仍然约有30%的患者在初诊发现时已经处于局部晚期。局部晚期肺癌患者差异性及异质性大,可伴有侵犯胸腔内脏器、肺门或纵隔淋巴结,手术难度以及风险较高,尽管部分患者能够获得手术切除机会,但术后仍存在复发率高、无进展生存期短等问题,总体疗效不佳,因此目前迫切需要加入一种全新的治疗方式改善这一问题。以免疫检查点抑制剂(ICI)为代表的癌症免疫疗法具有与既往传统化疗和靶向治疗不同的机制,目前已应用于多种实体瘤治疗中,部分患者存在生存获益。本文报道1例新辅助化疗联合程序性死亡受体-1(PD-1)抑制剂治疗驱动基因阴性局部晚期NSCLC有效的病例,为局部晚期NSCLC新辅助治疗提供了新思路。Lung cancer has become the malignant tumor with the highest incidence rate and mortality in the world.Among the pathological types of lung cancer,non-small cell lung cancer(NSCLC)accounts for about 80% of the total.Although the medical level is constantly improving,about 30% of patients are still in local advanced at the time of initial diagnosis.Patients with locally advanced lung cancer have great differences and heterogeneity,and may be accompanied by invasion of thoracic visceral organs,hilar or mediastinal lymph nodes.The operation is difficult and risk is high.Although some patients can obtain the opportunity of surgical resection,there are still problems such as high recurrence rate and short progression free survival,and the overall curative effect is poor.Therefore,there is an urgent need to add a new treatment to improve this problem.Cancer immunotherapy represented by immune checkpoint inhibitor(ICI)has different mechanism from traditional chemotherapy and targeted therapy.At present,it has been applied to the treatment of a variety of solid tumors,and some patients can gain survival benefits.This paper report a case of neoadjuvant chemotherapy combined with programmed death receptor-1(PD-1)inhibitor in the effective treatment of locally advanced NSCLC with negative driver gene.It provides a new idea for neoadjuvant therapy of locally advanced NSCLC.

关 键 词：非小细胞肺癌 免疫检查点抑制剂 新辅助治疗 程序性死亡受体-1 

分 类 号：R734.2[医药卫生—肿瘤]